Insulet (PODD) Stock Forecast, Price & News

Insulet (NASDAQ:PODD) Frequently Asked Questions

Is Insulet a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Insulet stock.
View analyst ratings for Insulet or view top-rated stocks.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Insulet.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.17. The medical instruments supplier had revenue of $295.40 million for the quarter, compared to analysts' expectations of $287.99 million. Insulet had a trailing twelve-month return on equity of 15.81% and a net margin of 3.91%. Insulet's quarterly revenue was up 17.1% compared to the same quarter last year.
View Insulet's earnings history.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.23 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion.

What price target have analysts set for PODD?

11 brokerages have issued twelve-month price targets for Insulet's stock. Their forecasts range from $230.00 to $350.00. On average, they anticipate Insulet's stock price to reach $302.33 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price.
View analysts' price targets for Insulet or view top-rated stocks among Wall Street analysts.

Who are Insulet's key executives?

Insulet's management team includes the following people:

• Ms. Shacey Petrovic, Pres, CEO & Director (Age 48, Pay $1.8M) (LinkedIn Profile)
• Mr. Wayde D. McMillan, Exec. VP,CFO & Treasurer (Age 52, Pay $969.46k) (LinkedIn Profile)
• Mr. Charles Alpuche, Exec. VP & COO (Age 62, Pay $1.05M) (LinkedIn Profile)
• Mr. Dan Manea, Sr. VP & Chief HR Officer (Age 55, Pay $841.64k)
• Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 51, Pay $918.47k) (LinkedIn Profile)
• Ms. Lauren Budden, VP, Chief Accounting Officer & Controller
• Ms. Deborah R. Gordon CPA, VP of Investor Relations
• Mr. Michael Spears, Sr. VP of Regulatory Affairs & Compliance (Age 57)
• Mr. John Wodick Kapples, Sr. VP, Sec. & Gen. Counsel (Age 62)
• Angela Geryak Wiczek, Sr. Director of Corp. Communications

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Insulet's key competitors?

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of PODD's competitors.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.95%), Clearbridge Investments LLC (2.45%), Primecap Management Co. CA (1.78%), Echo Street Capital Management LLC (1.16%), Goldman Sachs Group Inc. (0.85%) and Viking Global Investors LP (0.79%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Eric Benjamin, John A Fallon, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Viking Global Investors LP, Sumitomo Mitsui Trust Holdings Inc., Bank of Nova Scotia, Frontier Capital Management Co. LLC, Bank of New York Mellon Corp, Scout Investments Inc., and Loomis Sayles & Co. L P. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, John A Fallon, Sally Crawford, Shacey Petrovic, and Wayde D Mcmillan.
View insider buying and selling activity for Insulet or view top insider-selling stocks.

Which institutional investors are buying Insulet stock?

PODD stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Clearbridge Investments LLC, Echo Street Capital Management LLC, Ownership Capital B.V., Renaissance Technologies LLC, Blair William & Co. IL, Jag Capital Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Insulet or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $196.91.

How much money does Insulet make?

Insulet has a market capitalization of $13.65 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.629990 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 2,300 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120.